QCLS

Q/C Technologies Inc

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 75%
Negative

Neutral
GlobeNewsWire
1 month ago
Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli
New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, financial innovation and early-stage growth.
Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli
Positive
Invezz
1 month ago
Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR
Q/C Technologies In (NASDAQ: QCLS) soared another 60% on Thursday morning after former pharmaceutical executive Martin Shkreli touted the company as a “long idea”. According to him, the photonic computing firm could be trading at $100 per share, and that too in the near-term.
Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR
Neutral
GlobeNewsWire
2 months ago
Q/C Technologies Introduces Proprietary qc-LPU100™ Brand of Quantum-Class Laser Processing Units
Breakthrough LPUs designed to compute at quantum-class speed using natural light instead of electrical signals to achieve quantum computer speeds
Q/C Technologies Introduces Proprietary qc-LPU100™ Brand of Quantum-Class Laser Processing Units
Neutral
GlobeNewsWire
2 months ago
Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives
Dr. Frankel brings extensive knowledge and deep expertise that bridges advanced physics and quantum technologies New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C” or the “Company”), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Steven Frankel, Ph.D. as Senior Quantum Advisor.
Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives
Neutral
Business Wire
3 months ago
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“Q/C” or the “Company”) today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol “QCLS” on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol “TNFA.” The new name Q/C Technologies represents the Company's recent strategi.
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
Neutral
Business Wire
3 months ago
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals Inc. (Nasdaq: TNFA), (“TNF” or the “Company”) today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have.
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Neutral
Business Wire
4 months ago
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced its participation in the H.C. Wainwright & Co. 27th Annual Global Investment Conference taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. TNF's presentation is scheduled for Wednesday, September 10, 2025, at 8:00 a.m. ET. Presentation Details: Date and time: September 10, 2025, at 8:00 a.m. ET1 Location: Lotte New York Palace Hotel, New York City.
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neutral
Business Wire
4 months ago
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced the closing of a $7.0 million private placement financing of convertible preferred stock with the Company's largest strategic stockholder and other existing stockholders. The private placement involved the sale of 7,000 shares of preferred stock, with a stated value of $1,000 per share, convertible into 1,400,000 million shares of the Company's common stock at an initial conversion price.
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
Neutral
Business Wire
4 months ago
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an additional $3 million. The Company does so to help support TNF's recent acquisition of a license with LightSolver, Ltd. (“LightSolver”), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed.
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
Neutral
Business Wire
4 months ago
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced that it has entered into a licensing agreement for an innovative processing accelerator designed to expedite compute-intensive computations In partnership with LightSolver Ltd. (“LightSolver”), a company recognized by Gartner and the World Economic Forum for its breakthrough innovation. TNF holds exclusive rights to the use of its computing technology in cryptocurrency and blockchain app.
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications